Posttranslational modification of lipoproteins - A fatal attraction in metabolic disease? Commentary on: Hone et al., Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding

Journal of Alzheimer's Disease

Volumn 7, Issue 4, 2005, Pages 315-317

  Bierhaus, A ^a   Nawroth, P P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE;

CHOLESTEROL METABOLISM; FIBROBLAST CULTURE; GLYCATION; HUMAN; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN VARIANT; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY;

EID: 23944524332     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2005-7407     Document Type: Note

References (27)

1. B. Teter, ApoE-dependent plasticity in Alzheimer's disease, J Mol Neurosci 23 (2004), 167-179.
2. M. Sadowski et al., A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice, Am J Pathol 165 (2004), 937-948.
3. K.R. Bales et al., Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 96 (1999), 15233-15238.
4. K.R. Bales et al., Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition, Nat Genet 17 (1997), 263-264.
5. G.Y. Hsiung, A.D. Sadovnick and H. Feldman, Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging, Cmaj 171 (2004), 863-867.
6. R.M. Lane and M.R. Farlow, Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease, J Lipid Res 46 (2005), 949-968.
7. M. Orth et al., Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in whites, Arterioscler Thromb Vasc Biol 19 (1999), 1306-1315.
8. A.H. Smelt and F. de Beer, Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects, Semin Vasc Med 4 (2004), 249-257.
9. Q. Chen et al., APOE polymorphism and angiographic coronary artery disease severity in the Women's Ischemia Syndrome Evaluation (WISE) study, Atherosclerosis 169 (2003), 159-167.
10. M.I.E. Hone, M. Jeoung, T.H. Ji, S.E. Gandy and R.N. Martins, Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding, J Alzheimers Dis (2005).
11. K. Winkler et al., Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis, J Lipid Res 40 (1999), 447-455.
12. H. Scharnagl et al., The betaA4 amyloid peptide complexes to and enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway, Lab Invest 79 (1999), 1271-1286.
13. I.J. Martins, C. Vilcheze, B.C. Mortimer, R. Bittman and T.G. Redgrave, Sterol side chain length and structure affect the clearance of chylomicron-like lipid emulsions in rats and mice, J Lipid Res 39 (1998), 302-312.
14. R. Peila, B.L. Rodriguez and L.J. Launer, Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study, Diabetes 51 (2002), 1256-1262.
15. Y.M. Li and D.W. Dickson, Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease, Neurosci Lett 226 (1997), 155-158.
16. S. Araki et al., APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study, Diabetes Care 26 (2003), 2416-2420.
17. V.V. Shuvaev et al., Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site, Biochim Biophys Acta 1454 (1999), 296-308.
18. D. Stern, S.D. Yan, S.F. Yan and A.M. Schmidt, Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings, Adv Drug Deliv Rev 54 (2002), 1615-1625.
19. L.G. Bucciarelli et al., RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice, Circulation 106 (2002), 2827-2835.
20. O. Arancio et al., RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice, Embo J 23 (2004), 4096-4105.
21. A. Bierhaus et al., Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily, J Clin Invest 114 (2004), 1741-1751.
22. E. Steen et al., Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7 (2005), 63-80.
23. L. Gasparini et al., Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling, J Neurosci 21 (2001), 2561-2570.
24. C.J. Phiel, C.A. Wilson, V.M. Lee and P.S. Klein, GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides, Nature 423 (2003), 435-439.
25. L. Ho et al., Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease, Faseb J 18 (2004), 902-904.
26. J.W. Baynes, The role of AGEs in aging: causation or correlation, Exp Gerontol 36 (2001), 1527-1537.
27. L.J. Podewils et al., Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study, Am J Epidemiol 161 (2005), 639-651.